WO1995024185A1 - Novel pyrimidine nucleosides - Google Patents

Novel pyrimidine nucleosides Download PDF

Info

Publication number
WO1995024185A1
WO1995024185A1 PCT/US1994/002652 US9402652W WO9524185A1 WO 1995024185 A1 WO1995024185 A1 WO 1995024185A1 US 9402652 W US9402652 W US 9402652W WO 9524185 A1 WO9524185 A1 WO 9524185A1
Authority
WO
WIPO (PCT)
Prior art keywords
compound
alkyl
hydrogen
aralkyl
protecting group
Prior art date
Application number
PCT/US1994/002652
Other languages
French (fr)
Inventor
Oscar Acevedo
Martin G. Dunkel
Phillip Dan Cook
Original Assignee
Isis Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Pharmaceuticals, Inc. filed Critical Isis Pharmaceuticals, Inc.
Priority to PCT/US1994/002652 priority Critical patent/WO1995024185A1/en
Priority to AU65503/94A priority patent/AU6550394A/en
Publication of WO1995024185A1 publication Critical patent/WO1995024185A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06Pyrimidine radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07HSUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/33Chemical structure of the base

Definitions

  • This invention relates to the design and synthesis of certain 2- and 4-substituted pyrimidine nucleosides that are useful for incorporation into oligonucleotides.
  • the oligonucleotides are useful as diagnostic reagents, research reagents and in therapeutics.
  • oligonucleotides complementary to a specific target messenger RNA (mRNA) sequence are used.
  • mRNA messenger RNA
  • oligonucleotides are currently undergoing clinical trials for such use.
  • Oligonucleotides can serve as competitive inhibitors of transcription factors to modulate the action of transcription factors.
  • Several recent reports describe such interactions (see, Bielinska, et. al . ,
  • Oligonucleotides also have found use in diagnostic tests. Such diagnostic tests can be performed using biological fluids, tissues, intact cells or isolated cellular components.
  • oligonucleotides ability to hybridize with a complementary strand of nucleic acid.
  • Hybridization is the sequence specific hydrogen bonding of oligonucleotides via Watson-Crick and/or Hoogsteen base pairs to RNA or DNA. The bases of such base pairs are said to be complementary to one another.
  • Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of many other biological molecules as well as in the preparation of such other biological molecules.
  • PCR polymerase chain reaction
  • PCR reactions have seemingly "exploded" as more and more use of this very important biological tool are practiced.
  • the uses of PCR have extended into many areas in addition to those contemplated by its nobel laureate inventor. Examples of such new areas include forensics, paleontology, evolutionary studies and genetic counseling to name just a few. Primers are needed for each of these uses. Oligonucleotides, both natural and synthetic, serve as the primers. Oligonucleotides also are used in other laboratory procedures . A number of these uses are described in common laboratory manuals such as Molecular Cloning, A Laboratory Manual , Second Ed., J. Sambrook, et al . , Eds., Cold Spring Harbor Laboratory Press, 1989; and Current Protocols In Molecular Biology, F. M.
  • oligonucleotides To supply the users of oligonucleotides, many scientific journals now contain advertisements for either oligonucleotide precursors or for custom-synthesized oligonucleotides. This has become an important commercial use of oligonucleotides. Other oligonucleotides can be synthesized to have properties that are tailored for the desired use. Thus, a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents, and as therapeutic entities.
  • modifications are designed to increase binding to a target strand, to assist in identification of the oligonucleotide or an oligonucleotide-target complex, to increase cell penetration, to provide stability against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides, to provide a mode of disruption (terminating event) once sequence- specifically bound to a target, or to improve the pharmacokinetic properties of the oligonucleotides.
  • reactive functionalities can be tethered to an oligonucleotide and directed at phosphodiester and heterocyclic centers in target compounds.
  • the positioning of these functionalities may require the synthesis of C-2 and C-4 substituted pyrimidine nucleosides with the following general features: (a) preservation of Watson-Crick hybridization characteristics; (b) stability during automated DNA synthesis; and (c) the conformational rigidity of a carbon tether to accurately place functionalities near their target. Criteria (a) and (b) are not met by readily available 2-0- , 2-S-, or 2-N-alkyl pyrimidine nucleosides since these groups are sensitive to nucleophilic displacement.
  • the present invention provides novel C-2 and C-4 modified pyrimidine nucleosides and oligonucleosides.
  • the compounds of the invention have structure 1 or structure 2 :
  • J is N or CH
  • Q is halogen, hydrogen, C ⁇ C ⁇ alkyl, C ⁇ C ⁇ alkylamine, C 1 -C 20 alkyl-N-phthalimide, C ⁇ C ⁇ alkylimidazole, C ⁇ -C 20 alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor- omethyl, trifluoromethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulf
  • X x and X 2 independently are hydrogen, halogen, hydrox- yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxyla ino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, or groups that enhance the pharmacokinetic properties of oligonucleotides
  • the present invention also provides methods for preparing the compounds of the invention and synthetic intermediates employed in the methods.
  • the methods involve reacting 2,2'- or 2, 5' -anhydropyrimidines with a nucleophile to effect attack of the nucleophile at the 2-pyrimidine position.
  • the nucleophile can have general formula R 2 or can be a functional group that can be modified to have formula R 2 .
  • the methods involve reacting 4-halopyrimidines with substituted alkynes in the presence of an organometallic coupling reagent for a time and under reaction conditions effective to form a covalent bond between the alkyne and the pyrimidine 4-position.
  • the invention also provides methods for modulating the production or activity of a protein in an organism comprising contacting the organism with a compound according to the invention. It is preferred that the compound include a base sequence that is complementary to a RNA or DNA sequence that codes for the protein. This "targeting portion" of the compound is, thus selected to be complementary to the targeted portion of DNA or RNA such that the compound can bind to the target portion.
  • nucleosides that include 2- and 4-modified pyrimidine bases, and to more complex compounds that include the nucleosides.
  • nucleoside refers to a unit made up of a heterocyclic base and its sugar.
  • nucleotide refers to a nucleoside having a phosphate group on its 3' or 5 ' sugar hydroxyl group.
  • nucleosides unlike nucleotides, have no phosphate group.
  • Oligonucleotide refers to a plurality of joined nucleotide units formed in a specific sequence from naturally occurring bases and pentofuranosyl groups joined through a sugar group by native phosphodiester bonds. This term refers to both naturally occurring and synthetic species formed from naturally occurring subunits.
  • oligonucleotide analogs that is, compounds which function like oligonucleotides but which have non-naturally occurring portions. Oligonucleotide analogs can have altered sugar moieties, altered base moieties or altered inter-sugar linkages. For the purposes of this invention, an oligo ⁇ nucleotide analog having non-phosphodiester bonds, i.e., an altered inter-sugar linkage, is considered to be an "oligo- nucleoside.”
  • oligonucleoside thus refers to a plurality of nucleoside units joined by linking groups other than native phosphodiester linking groups.
  • oligomers is intended to encompass oligonucleotides, oligonucleotide analogs or oligonucleosides.
  • oligomers reference is made to a series of nucleosides or nucleoside analogs that are joined via either naturally occurring phosphodiester bonds or other, non-naturally occurring linkages.
  • the oligonucleosides of the invention preferably comprise from about 5 to about 50 nucleosides, each nucleoside having the same or different structure.
  • the targeting portions of the oligonucleosides preferably comprise about 8 to about 40 base nucleosides, more preferably about 12 to 20 base nucleosides.
  • an oligonucleoside of the invention include at least one 2- or 4-modified pyrimidine at its 3'- or 5' -terminus.
  • the oligonucleoside has 1-3 modified pyrimidines at its 3 ' - terminus.
  • the nucleosides of the invention can be linked with one another or with other nucleosides or oligonucleosides via a sugar linking group.
  • the linking groups can be any structure capable of linking sugar moieties of oligonucleosides to form the targeting portion of the compositions of this invention. It is preferred that these sugar linking groups comprise phosphodiester groups or derivatives thereof. Derivatives of the phosphodiester structure can include substitution of a sulphur, methyl, methyl oxide, or amine group for an oxygen.
  • the sugar phosphate nucleic acid backbone may be modified as a phosphorothioate, methylphosphonate, or phosphate alkylated moiety.
  • the phosphodiester linkage may also be replaced by a carbon or ether linkage.
  • the 2-substituted pyrimidine compounds of the invention are represented by the structures 1 and 2 :
  • J is N or CH
  • Q is halogen, hydrogen, C 1 -C 20 alkyl, C ⁇ C ⁇ alkylamine, C- L -C ⁇ alkyl-N-phthalimide, C-_-C 20 alkylimidazole, ⁇ -C ⁇ alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C 2 -C 20 alkenyl, C 2 -C 20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor- omethyl, trifluoro ethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulf
  • T 3 and T 5 independently are H, phosphate, an activated phosphate, a hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside;
  • Xr, and X 2 independently are hydrogen, halogen, hydrox ⁇ yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators,
  • R 2 when T 5 is a hydroxyl protecting group or together T 3 and one of X, or X 2 is a hydroxyl protecting group, then R 2 should not be CH 3 ; when T 3 and T 5 are OH or 0-benzoyl, then R 2 should not be CH 2 OC 6 H 5 .
  • protecting groups can be employed in the methods of the invention. See, e . g. , Beaucage, et al . , Tetrahedron 1992, 12, 2223.
  • protecting groups render chemical functionality inert to specific reaction conditions, and can be appended to and removed from such functionality in a molecule without substantially damaging the remainder of the molecule.
  • Representative hydroxyl protecting groups include t-butyldimethylsilyl (TBDMS) , t-butyldiphenyl- silyl (TBDPS) , dimethoxytrityl (DMTr) , monomethoxytrityl (M Tr) , and other hydroxyl protecting groups as outlined in the above-noted Beaucage reference.
  • Leaving groups according to the invention are chemical functional groups that can be displaced from carbon atoms by nucleophilic substitution.
  • Representative leaving groups include but are not limited to halogen, alkylsulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted aryl- sulfonyl, hetercyclcosulfonyl or trichloroacetimidate groups.
  • Preferred leaving groups include chloro, fluoro, bromo, iodo, p- (2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methyl- sulfonyl (mesylate) , p-methylbenzenesulfonyl (tosylate) , p- bromobenzenesulfonyl, trifluoromethylsulfonyl (triflate) , trichloroacetimidate, acyloxy, 2,2, 2-trifluoroethanesulfonyl, imidazolesulfonyl, and 2, 4, 6-trichlorophenyl groups.
  • Heterocycles according to the invention are functional groups that include atoms other than carbon in their cyclic backbone.
  • Intercalators according to the invention generally include non-carcinogenic, polycyclic aromatic hydrocarbons or heterocyclic moieties capable of intercalating between base pairs formed by a hybrid oligonucleotide/RNA target sequence duplex.
  • Intercalators can include naphthalene, anthracene, phenanthrene, benzonaphthalene, fluorene, carbazole, acridine, pyrene, anthraquinone, quinoline, phenylquinoline, xanthene or 2, 7-diazaanthracene groups.
  • Other intercalators believed to be useful are described by Denny, Anti -Cancer Drug Design 1989, 4 , 241.
  • Another intercalator is the ligand 6- [ [ [9- [ [6- (4-nitro- benzamido) hexyl] amino] acridin-4-yl] carbonyl] -amino] hexanoyl- pentafluorophenyl ester.
  • Reporter molecules are those compounds that have physical or chemical properties that allow them to be identified in gels, fluids, whole cellular systems, broken cellular systems and the like utilizing physical properties such as spectroscopy, radioactivity, colorimetric assays, fluorescence, and specific binding.
  • Particularly useful reporter molecules include biotin and fluorescein dyes.
  • Particularly useful as reporter molecules are biotin, fluore ⁇ scein dyes, alkaline phosphates, and horseradish peroxidase.
  • the term "depurination enhancing moiety” includes chemical moieties that are capable of enhancing the rate of depurination of a purine-containing nucleic acid species.
  • Depurination enhancing moieties enhance the rate of removal, break down, and/or loss of adenine and guanine nucleobases from adenosine and guanosine nucleotides. They also enhance the rate of the removal, break down, and/or loss of other purine- containing nucleotides such as 7-methylguanosine, 3-methyl- guanosine, wyosine, inosine, 2-aminoadenosine, and other "minor” or synthetic nucleotides.
  • Preferred depurination enhancing moieties are sulfur-containing compounds, including sulfur-containing heterocycles and both cyclic and alicyclic sulfonium compounds.
  • thiophene examples include but are not limited to thiophene, thianthrene, isothiazole, alkyl sulfonium salts, thiophenium salts, 1, 3-thiazolium salts, 1, 2-oxathiol- anium salts, alkyl 1,4-dithianium salts, alkyl thiazolium salts, thioniabicyclo [2,2, 1] heptane salts and 3aH-l, 6-dithia- 6a-thioniapentalene salts.
  • Anions for such salts include halide anions and other anions.
  • Conjugates are functional groups that improve the uptake of the compounds of the invention.
  • Representative conjugates include steroid molecules, reporter molecules, non- aromatic lipophilic molecules, reporter enzymes, peptides, proteins, water soluble vitamins, and lipid soluble vitamins, as disclosed by U.S. Patent Application Serial No. 782,374, filed October 24, 1991, and PCT Application US92/09196, filed October 23, 1992, the disclosures of which are incorporated herein by reference. Representative conjugates also are disclosed by Goodchild, Bioconjugate Chemistry 1990, 1 , 165. Activated phosphates according to the invention are disclosed by Beaucage, et al . , Tetrahedron 1982, 2223.
  • structure 1 can be equivalently represented by its tautomeric forms.
  • structure 1 in connection with the present invention is intended to include each of the following tautomeric structures:
  • the Eschenmoser sulfide contraction is limited by the stability and limited availability of functionalized ⁇ - haloketones .
  • 2-substituted pyrimidine nucleosides of the invention are synthesized by nucleophilic substitution of 2,2'- or 2 , 5 ' -anhydropyrimidines .
  • One preferred reaction sequence is shown in Scheme 1.
  • nucleoside structures 6a-d and 8. were isolated as yellowish oils with characteristic ultraviolet maxima near 320 nm; nucleoside structures 6a-d were found to be unstable.
  • the downfield shift of the amidine/enol signal in the X H-NMR spectra of these compounds is indicative of protons bound by N-3 and keto oxygen. Further, two tautomeric structures can be drawn which account for the vinylic character of the alpha proton of the tether.
  • the 4-substituted pyrimidine compounds of the invention are synthesized by metal-mediated coupling 2-halo- pyrimidines and substituted alkynes.
  • One preferred procedure is shown in Figure 1.
  • terminal alkynes are coupled to a 4-chloropyrimidine ribonucleoside by methods generally in accordance with Heck, "Palladium Reagents in Organic Synthesis” Academic Press, Orlando, FL (1985) .
  • a 4- chloro-2-trimethylsilylethoxy-pyrimidine, structure .12 . can be prepared by reaction of trimethylsilyethanol/n-butyllithium and 2,4-dichloropyrimidine in tetrahydrofuran (THF) at -20°C.
  • THF tetrahydrofuran
  • the compounds of this invention can be used in diagnostics, therapeutics, and as research reagents and kits.
  • the pyrimidine nucleosides of the invention are converted to their corresponding phosphoramidate nucleotide and incorporated into oligonucleotides.
  • they can be used in place of a standard or normal nucleotide to alter the properties of the diagnostic oligonucleotide reagent, as for instance, to increase the nuclease resistances of the oligonucleotide or to modulate (i.e., increase or decrease) hybridization of the oligonucleotide to a target.
  • Oligonucleotides that incorporate the compounds of the invention can be used for the selective binding of RNA for other research and diagnostic purposes. Such selective, strong binding is accomplished through interaction of RNA or DNA with compounds of the invention that are resistant to degradative nucleases and which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs .
  • a target RNA or DNA be preselected to comprise that portion of DNA or RNA which codes for a protein whose formation or activity is to be modulated.
  • the targeting portion of the compound to be employed is, thus, selected to be complementary to the targeted portion of DNA or RNA.
  • the compounds of the invention mimic the secondary structure of natural nucleic acid structures that bind to particular proteins.
  • the nucleic acid mimic can then be used for isolation and identification of the protein structure or for competitive binding to the protein structure.
  • One such nucleic acid structure is the TAR structure, which binds the tat protein.
  • oligonucleotide analogs are administered to animal suffering from a disease modulated by some protein. It is preferred to administer to patients suspected of suffering from ,:uch a disease an amount of oligonucleotide analog that is effective to reduce the symptomology of that disease.
  • One skilled in the art can determine optimum dosages and treatment schedules for such treatment regimens.
  • compounds of the invention hybridize to the mRNA of various pathogenic organisms.
  • Preferred compounds for such use include those incorporating a complementary sequences for herpes, papilloma and other viruses.
  • administer the therapeutic agents in accordance with this invention internally such as orally, intravenously, or intramuscularly.
  • Other forms of administration such as transdermally, topically, or intra- lesionally may also be useful.
  • Inclusion in suppositories may also be useful.
  • Use of pharmacologically acceptable carriers is also preferred for some embodiments.
  • Example 1 4-Chloro-2-trimethylsilylethoxy-pyrimidine, 12.
  • a solution of trimethylsilylethanol (10 g, 85 mmol) in 30 mL anhydrous THF was cooled to -68° C in a dry ice/isopropanol bath.
  • a solution of n-butyl lithium (33.8 mL, 2.5 M in THF) was added dropwise over 15 min. The solution was stirred for 10 min at this temperature and then added to a solution of 2, 4-dichloropyrimidine (12.62 g. 85 mmol) in 75 mL THF at -35 to -25° C
  • the final yellowish solution was allowed to come to room temperature under an argon atmosphere then stirred at this temperature for 1 hr.
  • the title compound was prepared in a manner similar to the preparation of 5- [ ( ert-butyl) diphenylsilyl] -2, 3-iso- propylidene-D-ribono-1,4-lactone as reported by Piccirilli, et al . , Helvetica Chimica Acta 1991, 74 , 397-406, substituting 5- ( tert-butyl) diphenylsilyl chloride for the 5- (tert- butyl) diphenylsilyl chloride. The product was obtained as a crystalline compound.
  • a suspension of bis-triphenylphosphine palladium (II) and copper (I) iodide in THF under argon is stirred for 10 mins.
  • To this suspension will be added 1-hexyne and triethyl- amine.
  • the resulting suspension will be stirred for an additional 10 mins followed by the addition of 3- ⁇ 2-0-methyl- 3,5- [-0- (1,1,3, 3-tetraisopropyl) -1, 3-disiloxanediyl] -D-ribo- furanosyl ⁇ -2-chloro-6-methoxy-pyridine.
  • the resulting mixture is stirred for 1 hr, filtered and evaporated.
  • the residue is dissolved in diethylether, treated with cold 0.1 N HCl and the organic phase is dried over MgS0 4 . Evaporation of the organic phase will yield the title compound.

Abstract

Novel 2- and 4-substituted pyrimidine nucleosides and oligonucleosides are provided, as are methods and intermediates useful in preparing same.

Description

NOVEL PYRIMIDINE NUCLEOSIDES
FIELD OF THE INVENTION
This invention relates to the design and synthesis of certain 2- and 4-substituted pyrimidine nucleosides that are useful for incorporation into oligonucleotides. The oligonucleotides, in turn, are useful as diagnostic reagents, research reagents and in therapeutics.
BACKGROUND OF THE INVENTION
It is well known that most of the bodily states in multicellular organisms, including most disease states, are effected by proteins. Such proteins, either acting directly or through their enzymatic or other functions, contribute in major proportion to many diseases and regulatory functions in animals and man. Classical therapeutics has generally focused upon interactions with such proteins in efforts to moderate their disease-causing or disease-potentiating functions. In newer therapeutic approaches, modulation of the actual production of such proteins is desired. By interfering with the production of proteins, the maximum therapeutic effect might be obtained with minimal side effects. It is the general object of such therapeutic approaches to interfere with or otherwise modulate gene expression which would lead to undesired protein formation.
One method for inhibiting specific gene expression is with the use of oligonucleotides. Oligonucleotides complementary to a specific target messenger RNA (mRNA) sequence are used. Several oligonucleotides are currently undergoing clinical trials for such use.
Transcription factors interact with double-stranded
DNA during regulation of transcription. Oligonucleotides can serve as competitive inhibitors of transcription factors to modulate the action of transcription factors. Several recent reports describe such interactions (see, Bielinska, et. al . ,
Science 1990, 250, 997-1000; and u, et al . , Gene 1990, 89,
203-209.) Oligonucleotides also have found use in diagnostic tests. Such diagnostic tests can be performed using biological fluids, tissues, intact cells or isolated cellular components.
As with the above gene expression inhibition, diagnostic use can take advantage of an oligonucleotides ability to hybridize with a complementary strand of nucleic acid. Hybridization is the sequence specific hydrogen bonding of oligonucleotides via Watson-Crick and/or Hoogsteen base pairs to RNA or DNA. The bases of such base pairs are said to be complementary to one another. Oligonucleotides are also widely used as research reagents. They are useful for understanding the function of many other biological molecules as well as in the preparation of such other biological molecules. One particular use, the use of oligonucleotides as primers in the reactions associated with polymerase chain reaction (PCR) , has been the cornerstone for the establishment of an ever expanding commercial business. The use of such PCR reactions has seemingly "exploded" as more and more use of this very important biological tool are practiced. The uses of PCR have extended into many areas in addition to those contemplated by its nobel laureate inventor. Examples of such new areas include forensics, paleontology, evolutionary studies and genetic counseling to name just a few. Primers are needed for each of these uses. Oligonucleotides, both natural and synthetic, serve as the primers. Oligonucleotides also are used in other laboratory procedures . A number of these uses are described in common laboratory manuals such as Molecular Cloning, A Laboratory Manual , Second Ed., J. Sambrook, et al . , Eds., Cold Spring Harbor Laboratory Press, 1989; and Current Protocols In Molecular Biology, F. M. Ausubel, et . al . , Eds., Current Publications, 1993. Such uses include Synthetic Oligonucleotide Probes, Screening Expression Libraries with Antibodies and Oligonucleotides, DNA Sequencing, In Vitro Amplification of DNA by the Polymerase Chain Reaction and Site- directed utagenesis of Cloned DNA from Book 2 of Molecular Cloning, A Laboratory Manual , ibid. and DNA-Protein Interactions and The Polymerase Chain Reaction from Vol. 2 of Current Protocols In Molecular Biology, ibid. . To supply the users of oligonucleotides, many scientific journals now contain advertisements for either oligonucleotide precursors or for custom-synthesized oligonucleotides. This has become an important commercial use of oligonucleotides. Other oligonucleotides can be synthesized to have properties that are tailored for the desired use. Thus, a number of chemical modifications have been introduced into oligonucleotides to increase their usefulness in diagnostics, as research reagents, and as therapeutic entities. These modifications are designed to increase binding to a target strand, to assist in identification of the oligonucleotide or an oligonucleotide-target complex, to increase cell penetration, to provide stability against nucleases and other enzymes that degrade or interfere with the structure or activity of the oligonucleotides, to provide a mode of disruption (terminating event) once sequence- specifically bound to a target, or to improve the pharmacokinetic properties of the oligonucleotides.
To serve some of the above-noted uses, reactive functionalities can be tethered to an oligonucleotide and directed at phosphodiester and heterocyclic centers in target compounds. The positioning of these functionalities may require the synthesis of C-2 and C-4 substituted pyrimidine nucleosides with the following general features: (a) preservation of Watson-Crick hybridization characteristics; (b) stability during automated DNA synthesis; and (c) the conformational rigidity of a carbon tether to accurately place functionalities near their target. Criteria (a) and (b) are not met by readily available 2-0- , 2-S-, or 2-N-alkyl pyrimidine nucleosides since these groups are sensitive to nucleophilic displacement. For example, deprotecting DNA oligomers containing S-alkylated moieties with concentrated ammonia likely would yield displacement products at C-2 and C-4 pyrimidine positions. In addition, 2-0- , 2-S-, and 2-N-alkyl groups would preclude the availability of an imino proton at N- 3, which is necessary for hydrogen bonding. Likewise, nucleosides having 2-N-alkyl groups at these positions would fail to meet criteria (b) and (c) due to their chemical instability and the spatial instability inherent in an inversion of configuration of a tertiary nitrogen. Accordingly, there remains a need in the art for novel 2- and 4-substituted pyrimidines that meet the design criteria set forth above.
OBJECTS OF THE INVENTION
It is one object of this invention to provide oligonucleotides for use in diagnostics, therapeutics and as research reagents. It is another object of this invention to provide oligonucleotides that effectively modulate the activity of RNA or DNA or proteins.
It is a further object to provide novel 2-substituted pyrimidines. These and other objects will become apparent to persons of ordinary skill in the art from a review of the present specification and appended claims.
SUMMARY OF THE INVENTION
In accordance with these and other objects, the present invention provides novel C-2 and C-4 modified pyrimidine nucleosides and oligonucleosides. In certain embodiments, the compounds of the invention have structure 1 or structure 2 :
Figure imgf000007_0001
wherein:
J is N or CH;
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of R2 and R4 is Q, =C(RA)-Q, C(RA) (RB)-C(RC) (RD) -Q, C(RA) =C(Rc) -Q or C≡C-Q;
R A/ RB, Rc and RD independently are H, SH, OH, NH2, or c ι _C 2o alkyl, or one of (RA) (RB) or (Rc) (RD) is =0;
Q is halogen, hydrogen, C^C^ alkyl, C^C^ alkylamine, C1-C20 alkyl-N-phthalimide, C^C^ alkylimidazole, Cι-C20 alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor- omethyl, trifluoromethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, 0- (hydroxyl protecting group) , a leaving group, a heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, a group that enhances the pharmacokinetic properties of oligonucleotides, a RNA cleaving moiety or a depurination enhancing group; T3 and T5 independently are H, phosphate, an activated phosphate, a hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside;
Xx and X2 independently are hydrogen, halogen, hydrox- yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxyla ino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, or groups that enhance the pharmacokinetic properties of oligonucleotides. For structure 1 , when T5 is a hydroxyl protecting group or together T3 and one of X-_ or X2 is a hydroxyl protecting group, then R2 should not be CH3; when T3 and T5 are OH or 0-benzoyl, then R2 should not be CH2OC6H5; and when R4 is Q then Q is not hydrogen, hydroxyl, thiol, amino or hydrogen. The present invention also provides methods for preparing the compounds of the invention and synthetic intermediates employed in the methods. In certain embodiments, the methods involve reacting 2,2'- or 2, 5' -anhydropyrimidines with a nucleophile to effect attack of the nucleophile at the 2-pyrimidine position. The nucleophile can have general formula R2 or can be a functional group that can be modified to have formula R2. In further embodiments, the methods involve reacting 4-halopyrimidines with substituted alkynes in the presence of an organometallic coupling reagent for a time and under reaction conditions effective to form a covalent bond between the alkyne and the pyrimidine 4-position.
The invention also provides methods for modulating the production or activity of a protein in an organism comprising contacting the organism with a compound according to the invention. It is preferred that the compound include a base sequence that is complementary to a RNA or DNA sequence that codes for the protein. This "targeting portion" of the compound is, thus selected to be complementary to the targeted portion of DNA or RNA such that the compound can bind to the target portion.
BRIEF DESCRIPTION OF THE DRAWING Fig. 1 shows certain synthetic methods according to the present invention.
DETAILED DESCRIPTION OF INVENTION
In a general sense, the present invention is directed to nucleosides that include 2- and 4-modified pyrimidine bases, and to more complex compounds that include the nucleosides. The term "nucleoside" as used in connection with this invention refers to a unit made up of a heterocyclic base and its sugar. The term "nucleotide" refers to a nucleoside having a phosphate group on its 3' or 5 ' sugar hydroxyl group. Thus, nucleosides, unlike nucleotides, have no phosphate group. "Oligonucleotide" refers to a plurality of joined nucleotide units formed in a specific sequence from naturally occurring bases and pentofuranosyl groups joined through a sugar group by native phosphodiester bonds. This term refers to both naturally occurring and synthetic species formed from naturally occurring subunits.
The compounds of the invention generally can be viewed as "oligonucleotide analogs", that is, compounds which function like oligonucleotides but which have non-naturally occurring portions. Oligonucleotide analogs can have altered sugar moieties, altered base moieties or altered inter-sugar linkages. For the purposes of this invention, an oligo¬ nucleotide analog having non-phosphodiester bonds, i.e., an altered inter-sugar linkage, is considered to be an "oligo- nucleoside." The term "oligonucleoside" thus refers to a plurality of nucleoside units joined by linking groups other than native phosphodiester linking groups. The term "oligomers" is intended to encompass oligonucleotides, oligonucleotide analogs or oligonucleosides. Thus, in speaking of "oligomers" reference is made to a series of nucleosides or nucleoside analogs that are joined via either naturally occurring phosphodiester bonds or other, non-naturally occurring linkages.
The oligonucleosides of the invention preferably comprise from about 5 to about 50 nucleosides, each nucleoside having the same or different structure. The targeting portions of the oligonucleosides preferably comprise about 8 to about 40 base nucleosides, more preferably about 12 to 20 base nucleosides. It is preferred that an oligonucleoside of the invention include at least one 2- or 4-modified pyrimidine at its 3'- or 5' -terminus. In certain embodiments, the oligonucleoside has 1-3 modified pyrimidines at its 3 ' - terminus. The nucleosides of the invention can be linked with one another or with other nucleosides or oligonucleosides via a sugar linking group. The linking groups can be any structure capable of linking sugar moieties of oligonucleosides to form the targeting portion of the compositions of this invention. It is preferred that these sugar linking groups comprise phosphodiester groups or derivatives thereof. Derivatives of the phosphodiester structure can include substitution of a sulphur, methyl, methyl oxide, or amine group for an oxygen. The sugar phosphate nucleic acid backbone may be modified as a phosphorothioate, methylphosphonate, or phosphate alkylated moiety. The phosphodiester linkage may also be replaced by a carbon or ether linkage.
In certain embodiments, the 2-substituted pyrimidine compounds of the invention are represented by the structures 1 and 2 :
Figure imgf000011_0001
wherein:
J is N or CH;
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of R2 and R4 is Q, =C(RA)-Q, C(RA) (RB)-C(RC) (R„) -Q, C(RA) =C(Rc) -Q or C=C-Q;
RA, RB, Rc and RD independently are H, SH, OH, NH2, or C. - C20 alkyl, or one of (RA) (RB) or (Rc) (RD) is =0;
Q is halogen, hydrogen, C1-C20 alkyl, C^C^ alkylamine, C-L-C^ alkyl-N-phthalimide, C-_-C20 alkylimidazole, ^-C^ alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor- omethyl, trifluoro ethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, 0- (hydroxyl protecting group) , a leaving group, a heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, a group that enhances the pharmacokinetic properties of oligonucleotides, a RNA cleaving moiety or a depurination enhancing group;
T3 and T5 independently are H, phosphate, an activated phosphate, a hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside; Xr, and X2 independently are hydrogen, halogen, hydrox¬ yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, or groups that enhance the pharmacokinetic properties of oligonucleotides.
For structure 1 , when T5 is a hydroxyl protecting group or together T3 and one of X, or X2 is a hydroxyl protecting group, then R2 should not be CH3; when T3 and T5 are OH or 0-benzoyl, then R2 should not be CH2OC6H5.
Preferred R2 and R4 groups include C(RA) =C(Rc) -Q, preferably where RA is OH, SH or NH2 and Rc is H, more preferably where Q is C-..20 or C-._6 alkyl; and C(RA) (RB)-C(RC) (RD) - Q, preferably where RA and RB are both hydrogen and Rc and RD together are =0.
Preferred structures are also those in which one of X- or X2 is hydrogen and the other is hydroxyl, or where both are hydrogen; where R4 is =0; where R5 is hydrogen or CH3; or where T3 is an activated phosphate and T5 is a hydroxyl protecting group; or where one of T3 or T5 is an oligonucleotide or an oligonucleoside, or both are H.
A wide variety of protecting groups can be employed in the methods of the invention. See, e . g. , Beaucage, et al . , Tetrahedron 1992, 12, 2223. In general, protecting groups render chemical functionality inert to specific reaction conditions, and can be appended to and removed from such functionality in a molecule without substantially damaging the remainder of the molecule. Representative hydroxyl protecting groups include t-butyldimethylsilyl (TBDMS) , t-butyldiphenyl- silyl (TBDPS) , dimethoxytrityl (DMTr) , monomethoxytrityl (M Tr) , and other hydroxyl protecting groups as outlined in the above-noted Beaucage reference. Leaving groups according to the invention are chemical functional groups that can be displaced from carbon atoms by nucleophilic substitution. Representative leaving groups include but are not limited to halogen, alkylsulfonyl, substituted alkylsulfonyl, arylsulfonyl, substituted aryl- sulfonyl, hetercyclcosulfonyl or trichloroacetimidate groups. Preferred leaving groups include chloro, fluoro, bromo, iodo, p- (2,4-dinitroanilino)benzenesulfonyl, benzenesulfonyl, methyl- sulfonyl (mesylate) , p-methylbenzenesulfonyl (tosylate) , p- bromobenzenesulfonyl, trifluoromethylsulfonyl (triflate) , trichloroacetimidate, acyloxy, 2,2, 2-trifluoroethanesulfonyl, imidazolesulfonyl, and 2, 4, 6-trichlorophenyl groups.
Heterocycles according to the invention are functional groups that include atoms other than carbon in their cyclic backbone.
Intercalators according to the invention generally include non-carcinogenic, polycyclic aromatic hydrocarbons or heterocyclic moieties capable of intercalating between base pairs formed by a hybrid oligonucleotide/RNA target sequence duplex. Intercalators can include naphthalene, anthracene, phenanthrene, benzonaphthalene, fluorene, carbazole, acridine, pyrene, anthraquinone, quinoline, phenylquinoline, xanthene or 2, 7-diazaanthracene groups. Other intercalators believed to be useful are described by Denny, Anti -Cancer Drug Design 1989, 4 , 241. Another intercalator is the ligand 6- [ [ [9- [ [6- (4-nitro- benzamido) hexyl] amino] acridin-4-yl] carbonyl] -amino] hexanoyl- pentafluorophenyl ester.
Reporter molecules are those compounds that have physical or chemical properties that allow them to be identified in gels, fluids, whole cellular systems, broken cellular systems and the like utilizing physical properties such as spectroscopy, radioactivity, colorimetric assays, fluorescence, and specific binding. Particularly useful reporter molecules include biotin and fluorescein dyes. Particularly useful as reporter molecules are biotin, fluore¬ scein dyes, alkaline phosphates, and horseradish peroxidase. The term "depurination enhancing moiety" includes chemical moieties that are capable of enhancing the rate of depurination of a purine-containing nucleic acid species. Depurination enhancing moieties enhance the rate of removal, break down, and/or loss of adenine and guanine nucleobases from adenosine and guanosine nucleotides. They also enhance the rate of the removal, break down, and/or loss of other purine- containing nucleotides such as 7-methylguanosine, 3-methyl- guanosine, wyosine, inosine, 2-aminoadenosine, and other "minor" or synthetic nucleotides. Preferred depurination enhancing moieties are sulfur-containing compounds, including sulfur-containing heterocycles and both cyclic and alicyclic sulfonium compounds. Specific examples include but are not limited to thiophene, thianthrene, isothiazole, alkyl sulfonium salts, thiophenium salts, 1, 3-thiazolium salts, 1, 2-oxathiol- anium salts, alkyl 1,4-dithianium salts, alkyl thiazolium salts, thioniabicyclo [2,2, 1] heptane salts and 3aH-l, 6-dithia- 6a-thioniapentalene salts. Anions for such salts include halide anions and other anions. Conjugates are functional groups that improve the uptake of the compounds of the invention. Representative conjugates include steroid molecules, reporter molecules, non- aromatic lipophilic molecules, reporter enzymes, peptides, proteins, water soluble vitamins, and lipid soluble vitamins, as disclosed by U.S. Patent Application Serial No. 782,374, filed October 24, 1991, and PCT Application US92/09196, filed October 23, 1992, the disclosures of which are incorporated herein by reference. Representative conjugates also are disclosed by Goodchild, Bioconjugate Chemistry 1990, 1 , 165. Activated phosphates according to the invention are disclosed by Beaucage, et al . , Tetrahedron 1982, 2223.
As will be recognized by those of ordinary skill in the art, the base portion of structure 1. can be equivalently represented by its tautomeric forms. Thus, the recitation of structure 1 in connection with the present invention is intended to include each of the following tautomeric structures:
Figure imgf000015_0001
There appear to have been few reported syntheses of 2-alkyl substituted pyrimidine nucleosides. Witkop, et al . , J. Amer. Chem. Soc . 1969, 91 , 7751 reported that treatment of a protected 2,5' -anhydrouridine with dimethylsulfoxonium methylid (DMSY) gave a 2-methylpyrimidin-4-one riboside after hydro- genolysis of the sulfoxonium group. 2-Methyl-pyrimidin-4-one ribonucleosides were also obtained when Rosenthal, et al . , Carbohydr. Res . 1980, 78, 33, examined the reaction of 2,2'- anhydrouridines with 1, 3-dithiane/n-butyllithium followed by desulfurization. Vorbrύggen, et al . , Angew. Chem. Int . Ed. 1976, 15 , 689, have investigated the Eschenmoser sulfide extraction of 2- and 4-S-phenacylated-2-thiouridines to yield 2- and 4-phenacetylpyrimidin-4-one ribonucleosides. However, these methods presented a number of problems. For example, attempts to synthesize the target nucleosides by DMSY chemistry according to Witkop' s work resulted in laborious purifications and low yields. The Eschenmoser sulfide contraction is limited by the stability and limited availability of functionalized α- haloketones . In certain embodiments, 2-substituted pyrimidine nucleosides of the invention are synthesized by nucleophilic substitution of 2,2'- or 2 , 5 ' -anhydropyrimidines . One preferred reaction sequence is shown in Scheme 1.
Figure imgf000016_0001
5 , 7 6 , 8 , 1 0 , 1 1
Scheme 1
At room temperature, the reaction of the lithium enolates of acetone, methylethylketone, 2-pentanone or 2-hexanone with a 3' -O-t-butyldiphenylsilyl-2,5' -anhydrothymidine 5_ (T3 = TBDMS, X-i = H, R5 = CH3 or H) yields the corresponding 2- (/β-ketoalkyl) - pyrimidin-4-one deoxynucleosides 6a-d (X-. = H; T5 = H; R2 = =CHC(0)CH3 (6a) , =CHC(0)CH2CH3 (6b) , =CHC(0) (CH2)2CH3 (6c), =CHC(0) (CH2)3CH3 (6d) ) following removal of the protecting groups. Likewise, reaction of the lithium enolate of hexanone with a protected 2-5' -anhydrouridine 7. (T3 = TBDMS, X = OTBDMS, R5 = CH3 or H) yields the corresponding 2- (2-hexanon-l- yl)pyrimidin-4-one ribonucleoside 8. (X- = ribo OH, T5 = T3 = H, R5 = CH3 or H, R2 = =CHC(0) (CH2)3CH3) . The nucleoside structures 6a-d and 8. were isolated as yellowish oils with characteristic ultraviolet maxima near 320 nm; nucleoside structures 6a-d were found to be unstable. The downfield shift of the amidine/enol signal in the XH-NMR spectra of these compounds is indicative of protons bound by N-3 and keto oxygen. Further, two tautomeric structures can be drawn which account for the vinylic character of the alpha proton of the tether. 3 ' , 5' - (di-0-MMTr, -DMTr, -TBDMS or -TBDPS) -2,2' -anhydrouridines 9. (T3 = T5 = MMTr, DMTr, TBDMS, TBDPS) can be used to synthesize the corresponding arabinosides. The reaction of structure 9. (T3 = T5 = TBDMS) with the lithium enolate of 2-hexanone followed by a deprotection of the intermediate produced the 2- (2-hexanon-l- yl) pyrimidin-4-one arabinonucleoside structure 1O (X. = ara OH, T3 = T5 = H, R5 = CH3 or OH, R2 = =CHC(0) (CH2)3CH3) in good yield. Also, it has been found that reaction of structure 9. (T3 = T5 = TBDMS) with the lithium enolate of 2-pentanone under standard conditions yields the protected 2-alkylated arabinonucleoside 11 (X. = ara OH, T3 = T5 = H, R5 = CH3 or H, R2 = =CHC(0) (CH2)2CH3) in 75% yield.
The 4-substituted pyrimidine compounds of the invention are synthesized by metal-mediated coupling 2-halo- pyrimidines and substituted alkynes. One preferred procedure is shown in Figure 1. In this approach, terminal alkynes are coupled to a 4-chloropyrimidine ribonucleoside by methods generally in accordance with Heck, "Palladium Reagents in Organic Synthesis" Academic Press, Orlando, FL (1985) . A 4- chloro-2-trimethylsilylethoxy-pyrimidine, structure .12., can be prepared by reaction of trimethylsilyethanol/n-butyllithium and 2,4-dichloropyrimidine in tetrahydrofuran (THF) at -20°C. Condensation of structure .12. and l-O-acetyl-2,3 , 5-tri-O- benzoyl-/?-D-ribofuranose is carried out using TMS- triflate/CH3CN generally according to the procedures of
Vorbruggen, et al . , Chem. Ber . 1981, 114 , 1234. Coupling of the 4 - chloro - l - ( 2 , 3 , 5 - tri -O - benzoyl - β - D- ribofuranosyl)pyrimidin-2-one, structure ,13., with an alkyne, such as 1-hexyne, and catalyzed by bis-triphenylphosphine palladium (II) dichloride/copper (I) iodide provides 4- (1- hexyn-l-yl)pyrimidin-2-one ribonucleoside, structure 14a (R = C4H9) . Similarly, the reaction of structure 13. with tri ethylsilylacetylene provides 4-trimethylsilylethynyl- pyrimidin-2-one ribonucleoside, structure 14b (R = TMS) . Conjugated alkyne nucleoside structures 14a,b can be reacted with H2S to yield 4- (2-thiol-l-alken-l-yl)pyrimidin-2- one ribonucleoside structures 16a (R = C4H9) and 16b (R = TMS) , or with methanolic ammonia to yield deprotected 4- (2-amino-l- alken-l-yl)pyrimidin-2-one riboside structures 17a (R = C4H9) and 17b (R = TMS) . Interestingly, the reaction of the 4- (2- thiol-l-hexen-l-yl)pyrimidin-2-one, .16., with ammonia displaces the thiol group and produces the ena ine structure 17a, identical to the product obtained from the reaction of alkyne 14a with ammonia. Hydration of structure 14a followed by deprotection of intermediate structure 15a {R. = benzoyl) yields the enolized 4- (2-hydroxy-1-hexen-l-yl)pyrimidin-2-one ribonucleoside, structure 18a (Rx = H) .
The enol nature of the 2- (5-ketoalkyl) - and 4-(β- ketoalkyl)pyrimidinone nucleoside analogs (6a-d, 8., 1_0, l_l and 18a) offer the potential for Watson-Crick hybridization. Because of this potential they can be considered as analogues of thymidine and cytidine. Thus hybridization of these compounds to adenosine and guanosine in a bifurcated bonding scheme is possible.
The compounds of this invention can be used in diagnostics, therapeutics, and as research reagents and kits. In certain uses in diagnostics and as research reagents, the pyrimidine nucleosides of the invention are converted to their corresponding phosphoramidate nucleotide and incorporated into oligonucleotides. For incorporation into oligonucleotides, they can be used in place of a standard or normal nucleotide to alter the properties of the diagnostic oligonucleotide reagent, as for instance, to increase the nuclease resistances of the oligonucleotide or to modulate (i.e., increase or decrease) hybridization of the oligonucleotide to a target.
Oligonucleotides that incorporate the compounds of the invention can be used for the selective binding of RNA for other research and diagnostic purposes. Such selective, strong binding is accomplished through interaction of RNA or DNA with compounds of the invention that are resistant to degradative nucleases and which hybridize more strongly and with greater fidelity than known oligonucleotides or oligonucleotide analogs .
For certain uses of the compounds of the invention, be it diagnostic use or therapeutic use, it is preferred that a target RNA or DNA be preselected to comprise that portion of DNA or RNA which codes for a protein whose formation or activity is to be modulated. The targeting portion of the compound to be employed is, thus, selected to be complementary to the targeted portion of DNA or RNA.
In accordance with a further preferred embodiment, the compounds of the invention mimic the secondary structure of natural nucleic acid structures that bind to particular proteins. The nucleic acid mimic can then be used for isolation and identification of the protein structure or for competitive binding to the protein structure. One such nucleic acid structure is the TAR structure, which binds the tat protein. By effectively mimicking TAR, compounds according to the invention bind the tat protein and thereby form a complex that can be isolated and identified using affinity chromatography.
For therapeutic use, oligonucleotide analogs are administered to animal suffering from a disease modulated by some protein. It is preferred to administer to patients suspected of suffering from ,:uch a disease an amount of oligonucleotide analog that is effective to reduce the symptomology of that disease. One skilled in the art can determine optimum dosages and treatment schedules for such treatment regimens.
In accordance with preferred embodiments, compounds of the invention hybridize to the mRNA of various pathogenic organisms. Preferred compounds for such use include those incorporating a complementary sequences for herpes, papilloma and other viruses.
It is generally preferred to administer the therapeutic agents in accordance with this invention internally such as orally, intravenously, or intramuscularly. Other forms of administration, such as transdermally, topically, or intra- lesionally may also be useful. Inclusion in suppositories may also be useful. Use of pharmacologically acceptable carriers is also preferred for some embodiments.
Additional objects, advantages, and novel features of this invention will become apparent to those skilled in the art upon examination of the following examples thereof, which are not intended to be limiting, wherein parts and percents are by weight unless otherwise indicated.
Example 1 4-Chloro-2-trimethylsilylethoxy-pyrimidine, 12. A solution of trimethylsilylethanol (10 g, 85 mmol) in 30 mL anhydrous THF was cooled to -68° C in a dry ice/isopropanol bath. A solution of n-butyl lithium (33.8 mL, 2.5 M in THF) was added dropwise over 15 min. The solution was stirred for 10 min at this temperature and then added to a solution of 2, 4-dichloropyrimidine (12.62 g. 85 mmol) in 75 mL THF at -35 to -25° C The final yellowish solution was allowed to come to room temperature under an argon atmosphere then stirred at this temperature for 1 hr. This solution was diluted with 200 mL of diethylether and washed with cold water (100 mL) , saturated NaHC03 (100 mL) and brine, then dried over MgS04, filtered and evaporated to yield a tan syrup. This syrup may be crystallized from hexanes at -60° C to yield 12 as a light yellow solid, 17.8 g (91 %) . XH-NMR (CDC13) : δ 8.36 (d, 1 H, H-6) ; 6.93 (d, 1 H, 5-H) ; 4.43 and 1.17 (t,t; 4 H; CH2CH2) ; 1.06 (bs, 9 H. TMS) .
Example 2
4-Chloro-l- (2,3,5-tri-0-benzoyl-β-D-ribofuranosyl)pyrimidin-2- one, 13..
A solution of 12 (8.17 g. 35.4 mmol) in 200 mL anhydrous acetonitrile is treated with l-O-acetyl-2, 3, 5-tri-O- benzoyl-D-ribofuranose (Pfanstiehl) at room temperature and under an atmosphere of argon. To this mixture is added TMS- triflate (6.11 mL, 35.4 mmol) and the mixture stirred at this temperature for 2 hr. Evaporation of the solvents in vacuo yielded an amber syrup which was immediately redissolved in 300 mL CH2C12, washed with cold, saturated NaHC03 (2 x 150 mL) , dried over magnesium sulfate, filtered and evaporated to a tan residue. Trituration of this residue with cold, anhydrous acetonitrile yielded analytically pure 13, 14.4 g (71 %) . 1H- NMR (DMSO-d6) : δ 8.39 (d, 1 H, 6-H, J6ιS=11.8 Hz) ; 8.0-7.4 (m, 15 H, aromatic) ; 6.68 (d, 1 H, H-5) ; 6.11 (d, 1H, H-l' , Jl,2= 2 Hz) ; 5.95 (m, 2 H, H-2' ,3' ) ; 4.85 (m, 1 H, H-4' ) ; 4.70 (m, 2 H, H-5' ,5") . Anal. Calcd f or C30H23N2O8Cl : C, 62.67; H, 4.03; N, 4.87. Found: C, 62.21; H, 3.92; N, 4.80.
Example 3
4- (1-Hexyn-l-yl) -1- (2,3, 5-tri-O-benzoyl-β-D-ribofuranosyl) - pyrimidin-2-one, 14a.
A suspension of bis-triphenylphosphine palladium (II) dichloride (0.35 g, 0.5 mmol) and copper (I) iodide (95 mg, 0.5 mmol) in THF (45 mL, distilled from Na-benzophenone ketyl) is sparged with dry argon gas for 10 min. To this suspension is added 1-hexyne (2.46 g, 30 mmol) followed by triethylamine (5 mL) . The suspension is stirred at room temperature under argon for 15 min. A similarly sparged solution of the 2-chloro-l- (2, 3 , 5-tri-O-benzoyl-b-D-ribofuranosyl)pyrimidin-4-one (13, 5.75 g, 10 mmol) in THF (15 mL) is added to the suspension of catalyst and the mixture stirred for 1 hr. The dark mixture is filtered through Celite and the filtrate evaporated in vacuo to afford a dark syrup. This syrup was triturated with cold diethylether, filtered and then dissolved in dichloromethane. The solution is washed with cold 1 N HC1, dried over magnesium sulfate and again evaporated in vacuo. The resulting residue was triturated with methanol to yield 14a as a white solid, 5.5 g, 88 %. XH-NMR (DMSO-d6) : δ 8.33 (d, 1 H, H-6, J6,5=7 Hz) ; 8.1- 7.4 (m, 15 H, aromatic) ; 6.53 (d, 1 H, H-5) ; 6.24 (s, 1 H, H- 1') ; 2.52, 1.50 and 0.94 (3 m, 9 H, n-butyl) . Anal. Calcd for C36H32N208: C, 69.67; H, 5.19; N, 4.51. Found: C, 69.32; H, 5.13; N, 4.44.
Example 4 2- (2-Trimethylsilylethynyl) 1- (2,3, 5-tri-O-benzoyl-β-D-ribo- furanosyl)pyrimidin-2-one, 14b.
Coupling of chloro nucleoside 13 ( 5.74 g, 10 mmol) with trimethylsilyl acetylene (4.9g, 50 mmol) according to the procedure described above gave 14b as a white amorphous solid, 5.12 g (80 %) . XH-NMR (DMSO-d6) : 8.37 (d, 1 H, H-6, J6>5 = 6.5 Hz) ; 8.1-7.4 (m, 15 H, aromatic) ; 6.60 (d, 1 H, H-5) ; 6.22 (s, 1 H, H-l') ; 0.29 (s, 9 H, TMS) . Anal. Calcd for C32H32N208Si : C, 66.02; H, 5.06; N, 4.40. Found: C, 65.68; H, 4.93; N, 4.39.
Example 5
4- (2-Hexanon-l-yl) -1- (2,3,5-tri-O-benzoyl-β-D-ribofuranosyl) - pyrimidin-2-one, 15a.
A solution of 14a (0.77 g, 1.2 mmol) in 50 mL acetone is treated with a 0.1 M solution of Hg(OAc)2 (15 mL) in aqueous acetic-H20 (1:1) and the mixture stirred at room temperature for 18 hr. The reaction is further diluted with dichloro¬ methane (100 mL) , washed with cold saturated NaHC03 solution, dried over magnesium sulfate and evaporated in vacuo. The resulting residue is flash-chromatographed using chloro- form/acetone 19:1 to afford a yellowish solid. This solid is triturated with cold methanol to afford 15a, 0.47 g, 59%. 1H- NMR (DMSO-d6) : 12.5 (s, 1 H, enol) ; 8.0-7.4 (m, 16 H, H-6 plus aromatic) ; 6.15 (d, 1 H, H-l', J = 2 Hz) ; 5.90 (m, 3 H, H- 5,2', 3') ; 5.39 (s, 1 H, vinylic, Jvlnyl, allyl = <1 Hz)) ; 2.30, 1-.47, 1.24 and 0.86 (4 m, 9 H, n-butyl) . Anal. Calcd for C36H34N209: C, 67.70; H, 5.37; N, 4.39. Found: C, 67.51; H, 5.28; N, 4.28.
Example 6
4- (2-Thiol-l-hexen-l-yl) -1- (2,3,5-tri-O-benzoyl-β-D-ribofuran- osyl)pyrimidin-2-one, 16a.
A solution of compound 14a (0.64 g) in THF is sparged with a steady stream of H2S gas for 3 min. The solution is then evaporated in vacuo and flash chromatographed using CHCl3/ethyl acetate (9:1) to afford 16a as an amber foam, 0.25 g (37%) . -NMR (DMSO-d6) : δ 15.3 (s, 1H, thiol) ; 6.43 (s, 1 H, vinylic, Jvιnyl/ allyl < 1 Hz); 6.23 (m, 2 H, H-l' and H-5) ; 2.7, 1.8, 1.3 and 0.9 (4 m, 9 H, n-butyl) . Anal. Calcd for C36H34N208S: C, 66.04; H, 5.23; N, 4.27; S, 4.89. Found: C, 66.10; H, 5.18; N, 4.13; S, 4.43. Example 7
4 - ( 2 -Amino- l -hexen- l -yl ) - l -β-D- ribofuranosyl -pyrimidin- 2 -one ,
17a .
A solution of 14a (1.2 g, 1.9 mmol) in methanolic ammonia (saturated at -20° C) was stirred in a pressure bottle for 18 hr. Evaporation of the solvents and flash chromatography of the residue using ethyl acetate/methanol (4:1) gave 17 a as a light yellow solid, 0.47 g (77 %) . XH-NMR (DMSO-d6) : δ 10.2 and 7.7 (2 bs, 2 H, NH2) ; 7.83 (d, 1 H, H-6, J6ι5 = 6.9 Hz) ; 5.78 (s, 1 H, H-l') ; 4.72 (s, 1 H, vinylic) ; 2.17, 1.50, 1.30 and 0.90 (4 m, 9 H, n-butyl) .
Example 8
4- (2-Amino-l-ethen-l-yl) -l-β-D-ribofuranosyl-pyrimidin-2-one,
17b A solution of 14b (1.2 g, 1.88 mmol) in 30 mL methanolic ammonia (saturated at -20° C) was stirred at room temperature for 18 hr. The solvents were evaporated in vacuo to a bright red syrup. This syrup was triturated with diethylether (Et20) (3 x 30 mL) then redissolved in methanol (MeOH) and reevaporated to give a solid orange foam. A portion of this foam was chromatographed on two preparative thin layer chromatography (TLC) plates using ethyl acetate/MeOH, 4:1 to give a sample for NMR. The purity of this sample was not sufficient to fit elemental analysis. Η-NMR (DMSO-d6) : δ 9.5 and 7.7 (2 bs, 2 H, NH2) ; 7.92 (d, 1 H, H-6, J6, 5 = 7 Hz) ; 7.0 (m, d w/D20 exch., 1 H, H- (b-vinylic) , Jb.a = 7.4 Hz) ; 5.77 (s, 1 H, H-l') ; 5.98 (d, 1 H, H-5) ; 4.74 (d, 1 H, H- (a-vinylic) .
Example 9
2-Thio-l- (3' ,5' -di-O-benzoyl-2' -O-methyl-β-D-ribofuranosyl) - pyrimidin-4-one
2-Thiouracil (1.282 g, 10 mmol) , a few crystals of ammonium sulfate, a few drops of trimethylsilyl chloride and
1, 1, 1, 3, 3 , 3-hexamethyldisilazane (HMDS, 20 ml) were refluxed overnight. The clear, greenish solution was evaporated under the exclusion of moisture. A solution of 2-O-methyl-l,3 , 5-tri- O-benzoyl-α-D-ribose (4.76 g, 10 mmol) in acetonitrile (50 ml) was added to give a clear solution. SnCl4 is added and the mixture became turbid and then immediately became clear thereafter. The mixture was stirred for three hours and then poured into a stirred mixture of saturated NaHC03 and dichloromethane (200/400 ml) . The organic layer was separated, dried over Na2S04, filtered and evaporated. The amorphous residue was crystallized from hot ethanol to yield colorless needles (1.895 g, 39%) . -N R (CDC13) : δ 10.3 (s, 1 H, NH) ; 7.8 (d, 1 H, H6) ; 6.7 (s, 1 H, HI') ; 5.7 (d, 1 H, H5) ; 3.6 (s, 3 H, OCH3) .
Example 10
2-Thio-S- (aceton-1-yl) -1- (3' , 5' -di-O-benzoyl-2' -O-methyl-β-D- ribofuranosyl) -pyrimidin-4-one Chloroacetone (0.35 ml, 4.35 mmol) was added to a solution of 2-thio-l- (3' ,5' -di-0-benzoyl-2' -O-methyl-β-D- ribofuranosyl) -pyrimidin-4-one in dichloromethane (920 ml) and triethylamine (0.81 ml, 5.8 mmol) . After 16 hrs water was added and the organic layer washed, dried with Na2S04, filtered and evaporated to yield the product as a homogeneous material by TLC. XH-NMR (CDC13) : δ 7.5 (d, 1 H, H6) ; 6.0 (s, 1 H, HI') ; 5.8 (d, 1 H, H5) ; 4.05 (s, 1 H, CH2) ; 3.4 (s, 3 H, 0CH3) ; 2.3 (s, 3 H, COCH3) .
Example 11 2- (Aceton-1-yl) -1- (3' ,5' -di-O-benzoyl-2' -O-methyl) -β-D-ribo- furanosyl) yrimidin-4-one
Crude 2-thio-S- (aceton-1-yl) -1- (3' ,5' -di-O-benzoyl-2' - O-methyl-β-D-ribofuranosyl) -pyrimidin-4-one was dissolved in toluene (20 ml) and triphenylphosphine and potassium t-butoxide (0.29 ml of a I N solution in THF, Aldrich) was added. The mixture was stirred at 125° C overnight. The solvent was evaporated and the residue was purified by flash column chromatography (5 cm; chloroform/ethyl acetate, 2:1) to give the product as a slightly yellowish foam (1.26 g, 80% from starting 2-thiouracil) . XH-NMR (CDC13) : δ 13.9 (b m, 1 H, N- -H- -0) ; 7.25 (s> 3 H, CH3) ; 4.98 (s, 1 H, CH) ; 3.5 (s, 3 H, OCH3) ; 2.2 (s, 1 H, COCH3) .
Example 12
2- (Hexan-2-on-l-yl) -l-{2" -deoxy-3' -0- [ (fcert-butyl) diphenyl- silyl] -β-D-eryt.hro-furanosyl}-pyrimidin-4-one
2-Hexanone (1.50 ml, 12 mmol) in THF (60 ml) was cooled to -70° C. Lithium diisopropyamide (2 M sol in THF, Aldrich) was added and the solution was stirred for 20 min maintaining the -70° C temperature. The solution was warmed to room temperature and 02, 5' -anhydro-3' -O- ( tert-butyldiphenyl- silyl) thymidine (1.74 g, 3.76 mmol) was added. The resulting solution became yellowish and after 35 min TLC indicated complete reaction. Water was added and the mixture neutralized carefully with 1 N HCl (alternately 3N acetic acid or 1 N H2S04 can be used) . The reaction mixture was partitioned between ether (150 ml) and water (50 ml) and layers separated. The organic layer was dried over Na2S04, filtered and evaporated. The residue was purified by flash column chromatography (5 cm, ethylacetate) to yield the product as a slightly yellowish foam (1.47 g, 69%) . "H-NMR (CDC13) : δ 14.1 (s, 1 H, N--H--0) ; 5.8 (m, 1 H, H-l') ; 4.8 (s, 1 H, CH) ; 2.3 (m, 1 H, CH2) ; 1.8 (m, 2 H, OH & CH3 5-pyr) ; 1.4, 1.6 (m, 4 H, CH2) ; 0.9 (t, 3 H, CH3 chain) .
Example 13 2 - (Hexan-2 -on-l-yl) -1- (2' -deoxy- -D-erythro-furanosyl) - pyrimidin-4-one
2- (Hexan-2-on-l-yl) -l-{2' -deoxy-3' - [ (tert-butyl) -di- phenylsilyl] -il-D- erythro-furanosyl} -pyrimidin-4-one in THF was deblocked with tetrabutylammonium fluoride (Bu4NF) using standard conditions (see, e . g. , Greene and Wuts in Protective Groups in Organic Synthesis, 2d ed., John Wiley & Sons, Inc., 1991, p. 83) to give the title compound. -NMR (CDC13) : δ 14.3 (s, 1 H, N- -H--0) ; 5.8 (t, 1 H, HI') ; 5.35, 5.15 (d,t, 2 H, 3' OH & 5' OH) . Example 14
2-Butyl-l-{2' -deoxy-3' -O- [ (tert-butyl) diphenylsilyl] -β-D- eryfchro-furanosyl}-pyrimidin-4-one
A solution of 0-2,5' -anhydro-3' -0- ( ert-butyldiphenyl- silyl) thymidine (0.87 g, 1.88 mmol) in THF (50 ml) was cooled to -70° C and butyllithium (3.75 ml of a 1.6 M solution in hexanes, Aldrich) was added. The mixture turned dark yellow immediately. TLC after 30 mins indicated complete reaction. The reaction mixture was warmed to room temperature, quenched with water (5 ml) and neutralized with 0.1 N HC1. The mixture was extracted with ether, the organic phase washed with H20, dried over Na2S04 and evaporated to give a yellow oil (1.08 g) . The oil was further purified by flash column chromatography (3 cm, chloroform/methanol 9:1) to give the product as a yellow foam (0.77 g, 79%) . XH-NMR (CDC13) : δ 6.1 (t, 1 H, HI') ; 2.9 (t, 2 H, CH2) ; 2.5 (br m, 1 H, 5' OH) ; 1.9 (s, 3 H, CH3 pyr) ; 1.7, 1.4 (m, 4 H, CH2) ; 0.9 (t, 3 H, CH3 chain) .
Example 15
2-Methyl-l- (2 ' , 3 ' , 5' -tri-O-benzoyl - & -D -ribofuranosyl) - pyrimidin-4-one
2-Methylpyrimidin-4-one (4.42 g, 40 mmol) and a few crystals of ammonium sulfate were refluxed in HMDS overnight . After cooling to room temperature the colorless solution was evaporated. A solution of l-O-acetyl-2, 3 , 5-tri-O-benzoyl-β-D- ribose (40 mmol, 20.18 g) in 1, 2-dichloroethane (200 ml) was added to the residue. Trimethylsilyl trifluoromethanesulfonate (TMSOTfl, 9.78 g, 44 mmol) was added and the resulting clear solution was stirred at room temperature for 2 hrs. The reaction mixture was poured in to saturated NaHC03 (300 ml) and extracted with chloroform (2 x 200 ml) . The organic phase was evaporated to give a colorless homogeneous foam (23.04 g, 104%, pure by NMR) . Example 16
2-Methyl-l- (-β-D-ribofuranosyl)pyrimidin-4-one
To a solution of 2-methyl-1- (2' ,3' ,5' -tri-O-benzoyl-β- -ribofuranosyl) -pyrimidin-4-one (13.86 g, 25 mmol) in methanol (150 ml) was added 4.37 N sodium methoxide solution in MeOH
(2.5 mmol, 0.1 eq.) . The solution was stirred overnight at room temperature and then evaporated. The residue was partitioned between water (100 ml) and dichloromethane (2 x 150 ml) . The aqueous layer was neutralized with Dowex 50 H+-form and evaporated. The orange oily residue was crystallized from ethanol/acetone 3:1 to give the title compound (2.37 g, 39%) .
"H-NMR (CDC13) : δ 8.1 (d, 1 H, H6) ; 6.0 (d, 1 H, H5) ; 5.65 (m,
2 H, HI', 2'-OH) ; 5.25, 5.2 (d,t, 2 H, 3' -OH, 5' -OH) ; 2.45 (s,
3 H, CH3) .
Example 17
5- [ (tert-Butyl)dimethylsilyl] -2,3-isopropylidene-D-ribono-l,4- lactone
The title compound was prepared in a manner similar to the preparation of 5- [ ( ert-butyl) diphenylsilyl] -2, 3-iso- propylidene-D-ribono-1,4-lactone as reported by Piccirilli, et al . , Helvetica Chimica Acta 1991, 74 , 397-406, substituting 5- ( tert-butyl) diphenylsilyl chloride for the 5- (tert- butyl) diphenylsilyl chloride. The product was obtained as a crystalline compound.
Example 18
3-{5' -O- [ (ter -Butyl) dimethylsilyl] -1' -hydroxyl-2' ,3' -O-iso- propylidene-I?-ribofuranosyl}-2-chloro-6-methoxy-pyridine and 5- {5' -O- [ ( er -Butyl) dimethylsilyl] -1' -hydroxyl-2' ,3' -O-isopro- pylidene -D -ribofuranosyl}-2-chloro-6-methoxy-pyridine Lithium diisopropyamide (12.6 mmol, 6.3 ml of a 2 M solution) was added to THF (30 ml) at -70° C. To the resulting solution was added 2-chloro-6-methoxypyridine (1.5 g, 1.25 ml, 10.50 mmol) and the resulting orange, clear solution was stirred at -70° C in a dry ice bath for 45 mins during which time the solution slowly turned yellow. 5- [ ( tert-Butyl) - dimethylsilyl] -2, 3-isopropylidene-D-ribono-l,4-lactone (1.44 g, 5.25 mmol) was added and after 30 mins the dry ice bath was removed and the reaction mixture slowly turned brown as it warmed to room temperature. After 3 hrs at room temperature the reaction was quenched with water and extracted with ether. The combined organic phase was washed with brine, dried over MgS04 and evaporated to give a yellow oil (2.28 g) of a mixture of the a and β isomers of the title compounds.
Example 19 3-{5' -0- [ (tert-Butyl)dimethylsilyl] -2' ,3' -O-isopropylidene-D- ribofuranosyl}-2-chloro-6-methoxy-pyridine
To a solution of the isomeric mixture of the above 1'- hydroxy compounds in toluene under N2 in an ice bath will be added triethylsilane (Et3SiH, 2 equiv.) and BF3-Et20. The mixture is stirred and allowed to come to room temperature. After 2 hours the mixture will be chromatographed on a silica gel column eluted with ethyl acetate/hexanes. The fractions containing the desired 3 β isomer are pooled to yield the product.
Example 20
3-{5'-0- t (tert-Butyl)dimethylsilyl] -2" ,3' -O-isopropylidene-β-D- ribofuranosyl}-2- (1-hexyl-l-yl) -6-methoxy-pyridine
A suspension of bis-triphenylphosphine palladium (II) and copper (I) iodide in THF under argon is stirred for 10 mins. To this suspension will be added 1-hexyne and triethyl- amine. The resulting suspension will be stirred for an additional 10 mins followed by the addition of 3-{5' - O- [( ert- butyl)dimethylsilyl] -2' ,3' -O-isopropylidene-D-ribofuranosyl}-2- chloro-6-methoxy-pyridine. The resulting mixture is stirred for 1 hr, filtered and evaporated. The residue is dissolved in diethylether, treated with cold 0.1 N HC1 and the organic phase is dried over MgS04. Evaporation of the organic phase will yield the title compound. Example 21
2- (2-Amino-l-hexen-l-yl) -3-{5' -O- [ (fcerfc-Butyl)dimethylsilyl] -
2' ,3' -0-isopropylidene-β-D-ribofuranosyl}-6-methoxy-pyridine
3- {5' -O- [ ( ert-Butyl) dimethylsilyl] -2 ' , 3 ' -O-iso- propy1idene-D-ribofuranosyl } -2- (1-hexyl-1-yl) -6-methoxy- pyridine will be treated in a pressure bottle with methanolic ammonia (saturated at -20° C) for 18 hours with stirring. The solvent will be evaporated and the residue purified by flash chromatography to give the title compound.
Example 22
2- (2-Amino-l-hexen-l-yl) -3- (2' , 3' -O-isopropylidene-β-D-ribo- furanosyl}-6-methoxy-pyridine
2- (2-Amino-l-hexen-l-yl) -3-{5' -O- [ (tert-butyl) -di¬ methylsilyl] -2' ,3' -O-isopropylidene-D-ribofuranosyl}-6-methoxy- pyridine in THF will be treated with Bu4NF at room temperature for 30 mins. The resulting solution will be evaporated and the residue chromatographed on silica gel eluted with MeOH/CHCl2 to give the title compound.
Example 23 2- (2-Amino-l-hexen-l-yl) -3- (β-D-ribofuranosyl}-pyrid-6-one
2- (2-Amino-l-hexen-l-yl) -3- (2' ,3' -O-isopropylidene-β- D-ribofuranosyl} -6-methoxy-pyridine will be dissolved in water and treated with 1 N HC1 to remove the isopropylidene groups and concurrently hydrolyze the methoxy function to the corresponding 6-pyridone. The resulting solution is extracted with CH2C12, the organic phase is washed with saturated bicarbonate, dried over MgS04 and evaporated. The residue is purified by chromatography on a silica gel column. The product containing fractions will be pooled and evaporated to yield the title compound. Example 24
3,5- [0- (1,1,3,3-Tetraisopropyl) -1,3-diεiloxanediyl] -D-ribono-
1,4-lactone.
D-Ribono-1, 4-lactone and 1, 3-dichloro-1, 1, 3 , 3-tetra- isopropyldisiloxane are stirred together in dry pyridine for 16 hrs at 25° C. The solvent is evaporated and the resulting oil will be dissolved in CH2C12, washed with saturated sodium bicar¬ bonate and the organic layer added to a silica gel column. The product is eluted from the column with methylene chloride/meth- anol and the appropriate fractions, combined and evaporated to yield the title compound.
Example 25
2-0-Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxanedi- yl] -D-ribono-l,4-lactone 3,5- [0- (1,1,3,3-Tetraisopropyl) -1, 3-disiloxanediyl] -D- ribono-1,4-lactone will be treated with CH3I and Ag20 at 40° C overnight generally in accordance with the procedure of Inoue, et al . , Nucleic Acids Research 1987, 15, 6131 to give the title compound.
Example 26
3-{2-0-Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxane- diyl] -D-ribofuranosyl}-2-chloro-6-methoxy-pyridine and 5-{2-0- Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxanediyl] -D- ribof ranosyl}-2-chloro-6-methoxy-pyridine Lithium diisopropylamide (as a 2 M solution) is added to THF (30 ml) at -70° C. To the resulting solution is added 2-chloro-6-methoxypyridine and the resulting solution stirred at -70° C in a dry ice bath for 45 mins. 2-0-Methyl-3, 5- [-0- (1,1,3, 3-tetraisopropyl) -1, 3-disiloxanediyl] -D-ribono-1, 4- lactone will be added and after 30 mins the dry ice bath removed and the reaction mixture slowly allowed to warm to room temperature. After 3 hrs at room temperature the reaction is quenched with water and extracted with ether. The combined organic phase is washed with brine and dried over MgS04 and evaporated to yield an oil that of a mixture of the α; and β isomers of the title compounds.
Example 27
3-{2-0-Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxane- diyl] -β-D-ribofuranosyl}-2-chloro-6-methoxy-pyridine
To a solution of the isomeric mixture of the corresponding 1' -hydroxy compounds in toluene under N2 in an ice bath is added Et3SiH (2 equiv.) and BF3-Et20. The mixture is stirred and allowed to come to room temperature. After 2 hours the mixture will be chromatographed on a silica gel column eluted with ethyl acetate/hexanes. The fractions containing the desired 3 β isomer are pooled to yield the product .
Example 28 3-{2-0-Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxane- diyl] -β-D-ribofuranosyl}-2- (1-hexyn-l-yl) -6-methoxy-pyridine
A suspension of bis-triphenylphosphine palladium (II) and copper (I) iodide in THF under argon is stirred for 10 mins. To this suspension will be added 1-hexyne and triethyl- amine. The resulting suspension will be stirred for an additional 10 mins followed by the addition of 3-{2-0-methyl- 3,5- [-0- (1,1,3, 3-tetraisopropyl) -1, 3-disiloxanediyl] -D-ribo- furanosyl} -2-chloro-6-methoxy-pyridine. The resulting mixture is stirred for 1 hr, filtered and evaporated. The residue is dissolved in diethylether, treated with cold 0.1 N HCl and the organic phase is dried over MgS04. Evaporation of the organic phase will yield the title compound.
Example 29
3-{2-0-Methyl-3,5- [-0- (1,1,3,3-tetraisopropyl) -1,3-disiloxane- diyl] -β-D-ribofuranosyl}-6-methoxy-2- (2-thiol-1-hexen-l-yl) - pyridine
3-{2-0-Methyl-3,5- [-0- (1, 1, 3 , 3-tetraisopropyl) -1,3- disiloxanediyl] -D-ribofuranosyl} -2- (1-hexyl-1-yl) -6-methoxy- pyridine in THF will be treated with a steady stream of H2S for 3 mins with stirring. The solvent will be evaporated and the residue purified by flash chromatography to give the title compound.
Example 30 3- (2-O-Methyl-β-D-ribofuranosyl) -2- (2-thiol-1-hexen-l-yl) - pyrid-6-one
3-{2-0-Methyl-3,5- [-0- (1, 1,3, 3-tetraisopropyl) -1,3-di- siloxanediyl] -D-ribofuranosyl}-6-methoxy-2- (2-thiol-l-hexen-l- yl) -pyridine will be treated with 3 N HCl to remove the tetraisopropyldisiloxanediyl protecting group and hydrolyze the 6-methoxy moiety. The resulting solution will extracted with CH2C12 washed with saturated bicarbonate, dried over MgS04 and the organic phase evaporated. The residue will be chromato¬ graphed on silica gel eluted with MeOH/CHCl2 to give the title compound.
Those skilled in the art will appreciate that numerous changes and modifications may be made to the preferred embodiments of the invention and that such changes and modifications may be made without departing from the spirit of the invention. It is therefore intended that the appended claims cover all such equivalent variations as fall within the true spirit and scope of the invention.

Claims

What is claimed is
1. A compound of the structure
Figure imgf000033_0001
wherein:
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of
R2 and R4 is Q, =C(RA)-Q, C(RA) (RB)-C(RC) (RD) -Q, C(RA) =C(Rc) -Q or C≡C-Q ;
RA, RB, Rc and RD independently are H, SH, OH, NH2, or C-, -C20 alkyl, or one of (RA) (RB) or (Rc) (RD) is =0; Q is halogen, hydrogen, C1-C20 alkyl, CJ-CJO alkylamine,
C1-C20 alkyl-N-phthalimide, C-, -C20 alkylimidazole, C^C^ alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor- omethyl, trifluoromethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, 0- (hydroxyl protecting group) , a leaving group, a heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhances the pharmacodynamic properties of oligonucleotides, a group that .enhances the pharmacokinetic properties of oligonucleotides, a RNA cleaving moiety or a depurination enhancing group; T3 and T5 independently are H, phosphate, an activated phosphate, a hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside;
Xx and X2 independently are hydrogen, halogen, hydrox- yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, or groups that enhance the pharmacokinetic properties of oligonucleotides; and provided that when T5 is a hydroxyl protecting group or together T3 and one of X-, or X2 is a hydroxyl protecting group, then R2 is not CH3; and that when T3 and T5 are OH or 0- benzoyl, then R2 is not CH20C6H5; and that when R4 is Q, then Q is not hydrogen, hydroxyl, thiol, amino or hydrogen.
2. A compound of claim 1 wherein one of X-. and X2 is hydrogen and the other is hydroxyl.
3. A compound of claim 1 wherein both of X. and X2 are hydrogen.
4. A compound of claim 1 wherein R2 is halogen.
5. A compound of claim 4 wherein R2 is chlorine.
6. A compound of claim 1 wherein R4 is =0.
7. A compound of claim 1 wherein R5 is H.
8. A compound of claim 1 wherein R5 is CH3.
9. A compound of claim 1 wherein T3 and T5 are both
H.
10. A compound of claim 1 wherein T3 is an activated phosphate and T5 is a hydroxyl protecting group.
11. A compound of claim 1 wherein at least one of T3 or T5 is an oligonucleotide or an oligonucleoside.
12. A compound of claim 1 wherein one of R2 or R4 is C(RA) (RB)-C(RC) (RD)-Q.
13. A compound of claim 12 wherein RA and RB are both hydrogen, and (Rc) (RD) is =0.
14. A compound of claim 13 wherein Q includes a sulfur containing heterocycle and a linking group covalently bound between said C(0) and said sulfur containing heterocycle.
15. A compound of claim 13 wherein said linking group is C-L-Cg alkyl, C2-C20 alkenyl or C2-C20 alkynyl.
16. A compound of claim 1 wherein one of R2 or R4 is C(RA)=C(RC)-Q.
17. A compound of claim 16 wherein RA is OH, SH or NH2; and Rc is hydrogen.
18. A compound of claim 17 wherein Q is C^C^ alkyl.
19. A compound of claim 17 wherein Q is
Figure imgf000035_0001
alkyl .
20. A compound of the structure
Figure imgf000036_0001
wherein:
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of R2 and R4 is =C(RA)-Q, C(RA) (RB)-C(RC) (RD) -Q or C(RA) =C(Rc) -Q;
RA, RB, Rc and RD independently are H, SH, OH or NH2, or one of (RA) (RB) or (Rc) (RD) is =0;
Q is halogen, hydrogen, C^C^ alkyl, C- -C2Q alkylamine, C1-C20 alkyl-N-phthalimide, C1-C20 alkylimidazole, ^-C^ alkylbis-imidazole, imidazole, bis-imidazole, amine or N- phthalimide;
T3 and T5 independently are H, phosphate, an activated phosphate, hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside; X. and X2 independently are hydrogen, hydroxyl or 0-
(hydroxyl protecting group) ; and provided that when T5 is a hydroxyl protecting group or together T3 and one of X-, or X2 is a hydroxyl protecting group, then R2 is not CH3; and that when T3 and T5 are OH or 0- benzoyl, then R2 is not CH2OC6H5 and the when R4 is Q, Q is not hydrogen, hydroxyl, thiol, amino or hydrogen..
21. A compound of claim 20 wherein one of X. and X2 is hydrogen and the other is hydroxyl .
22. A compound of claim 20 wherein both of X-. and X2 are hydrogen.
23. A compound of claim 20 wherein R2 is halogen.
24. A compound of claim 23 wherein R2 is chlorine.
25. A compound of claim 20 wherein R4 is =0.
26. A compound of claim 20 wherein R5 is H.
27. A compound of claim 20 wherein Rs is CH3.
28. A compound of claim 20 wherein T3 and T5 are both H.
29. A compound of claim 20 wherein T3 is an activated phosphate and T5 is a hydroxyl protecting group.
30. A compound of claim 20 wherein at least one of
T3 or T5 is an oligonucleotide or an oligonucleoside.
31. A compound of claim 20 wherein one of R2 or R4 is C(RA) (RB)-C(RC) (RD)-Q.
32. A compound of claim 31 wherein RA and RB are both hydrogen; and (Rc) (RD) is =0.
33. A compound of claim 20 wherein one of R2 is or R4 is C(RA)=C(RC) -Q.
34. A compound of claim 33 wherein RA is OH, SH or NH2; and Rc is hydrogen.
35. An oligonucleoside containing at least one nucleoside of the structure:
Figure imgf000038_0001
wherein:
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of R2 and R4 is Q, C(RA) (RB)-C(RC) (RD) -Q, C(RA) =C(Rc) -Q or C≡C-Q; A RB, Rc and RD independently are H, SH, OH, NH2 or C^C^ alkyl, or one of (RA) (RB) or (Rc) (RD) is =0;
Q is halogen, hydrogen, Cx-C20 alkyl, C-, -C2 , alkylamine, c ι~C20 alkyl-N-phthalimide, ^C^ alkylimidazole, C1-C20 alkylbis-imidazole, imidazole, bis-imidazole, N-phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluoromethyl, trifluoro- methoxy, 0-alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S- aralkyl, NH-aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, 0-
(hydroxyl protecting group) , a leaving group, a heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhance the pharmacodynamic properties of oligonucleotides, a group that enhance the pharmacokinetic properties of oligonuc¬ leotides, a RNA cleaving moiety or a depurination enhancing group;
X-, and X2 independently are hydrogen, halogen, hydrox- yl., 0- (hydroxyl protecting group), thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, groups that enhance the pharmacokinetic properties of oligonucleotides; and
T3 and T5 independently are H, a nucleoside or an oligonucleoside.
36. An oligonucleoside containing at least one nucleoside of the structure:
Figure imgf000039_0001
wherein:
R5 is H or CH3; one of R2 and R4 is =0, =NH, or =NH2 +; and the other of R2 and R4 is C(RA) (RB)-C(RC) (RD) -Q or C(RA)=C(Rc) -Q;
RA, RB, Rc and RD independently are H, SH, OH or NH2, or one (RA) (RB). or (Rc) (RD) is =0;
Q is halogen, hydrogen, C1-C20 alkyl, C^C^ alkylamine, c ι -C 2o alkyl-N-phthalimide, C1-C20 alkylimidazole, C1-C20 alkylbis-imidazole, imidazole, bis-imidazole, amine or N- phthalimide;
X- and X2 independently are hydrogen, hydroxyl or 0- (hydroxyl protecting group) ; and
T3 and T5 independently are H, a nucleoside, or an oligonucleoside that is joined to said structure.
37. A .process of treating an organism having a disease characterized by the undesired production of a protein, comprising contacting the organism with a compound of claim 1.
38. A method of modulating the production or activity of a protein in an organism comprising contacting the organism with a compound of claim 1.
39. A pharmaceutical composition comprising a compound of claim 1 in a pharmaceutically effective carrier.
40. A compound of the structure
Figure imgf000040_0001
wherein:
J is N or CH; R4 is =0, =NH, or =NH2 +;
R2 is Q, =C(RA)-Q, C(RA) (RB)-C(RC) (RD)-Q, C(RA)=C(Rc) -Q or C≡C-Q; RA, RB, Rc and RD independently are H, SH, OH, NH2 or
C1-C20 alkyl, or one of (RA) (RB) or (Rc) (RD) is =0;
Q is halogen, hydrogen, C-. -C20 alkyl, C1-C20 alkylamine, C1-C20 alkyl-N-phthalimide, C1-C20 alkylimidazole, C1-C20 alkylbis-imidazole, imidazole, bis-imidazole, amine, N- phthalimide, C2-C20 alkenyl, C2-C20 alkynyl, hydroxyl, thiol, keto, carboxyl, nitrates, nitro, nitroso, nitrile, trifluor¬ omethyl, trifluoromethoxy, 0-alkyl, S-alkyl, NH-alkyl, N- dialkyl, 0-aralkyl, S-aralkyl, NH-aralkyl, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, 0- (hydroxyl protecting group) , a leaving group, a 'heterocycle, an intercalator, a reporter molecule, a conjugate, a polyamine, a polyamide, a polyethylene glycol, a polyether, a group that enhance the pharmacodynamic properties of oligonucleotides, a group that enhance the pharmacokinetic properties of oligonucleotides, a RNA cleaving moiety or a depurination enhancing group;
T3 and T5 independently are H, phosphate, an activated phosphate, hydroxyl protecting group, a nucleoside, a nucleotide, an oligonucleotide or an oligonucleoside; and
X- and X2 independently are hydrogen, halogen, hydrox¬ yl, 0- (hydroxyl protecting group) , thiol, carboxyl, nitrate, nitro, nitroso, nitrile, trifluoromethyl, trifluoromethoxy, 0- alkyl, S-alkyl, NH-alkyl, N-dialkyl, 0-aralkyl, S-aralkyl, NH- aralkyl, amino, azido, hydrazino, hydroxylamino, isocyanato, sulfoxide, sulfone, sulfide, disulfide, silyl, heterocyclic, alicyclic, carbocyclic, intercalators, reporter molecules, conjugates, polyamines, polyamides, polyethylene glycols, poly- ethers, groups that enhance the pharmacodynamic properties of oligonucleotides, or groups that enhance the pharmacokinetic properties of oligonucleotides.
41. A method of preparing a compound according to claim 1, comprising contacting a 2,2' -anhydropyrimidine with a nucleophile having formula R2 under conditions effective to form a covalent bond between said nucleophile and the 2- position of said pyrimidine.
42. A method of preparing a compound according to claim 1, comprising contacting a 2, 5' -anhydropyrimidine with a nucleophile having formula R2 under conditions effective to form a covalent bond between said nucleophile and the 2- position of said pyrimidine.
43. A method of preparing a compound according to claim 1 wherein R4 is C≡C-Q, comprising contacting a 4-halo- pyrimidine with an alkyne having formula HC=C-Q in the presence of an organometallic coupling reagent for a time and under reaction conditions effective to form a covalent bond between said alkyne and the 2-position of said pyrimidine.
PCT/US1994/002652 1994-03-11 1994-03-11 Novel pyrimidine nucleosides WO1995024185A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/US1994/002652 WO1995024185A1 (en) 1994-03-11 1994-03-11 Novel pyrimidine nucleosides
AU65503/94A AU6550394A (en) 1994-03-11 1994-03-11 Novel pyrimidine nucleosides

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1994/002652 WO1995024185A1 (en) 1994-03-11 1994-03-11 Novel pyrimidine nucleosides

Publications (1)

Publication Number Publication Date
WO1995024185A1 true WO1995024185A1 (en) 1995-09-14

Family

ID=22242341

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002652 WO1995024185A1 (en) 1994-03-11 1994-03-11 Novel pyrimidine nucleosides

Country Status (2)

Country Link
AU (1) AU6550394A (en)
WO (1) WO1995024185A1 (en)

Cited By (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000040590A2 (en) * 1999-01-05 2000-07-13 Bio Merieux Functionalised polynucleotide compound, optionally marked and method for detecting a target nucleic acid
US6090932A (en) * 1994-06-22 2000-07-18 Proligo Llc Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
EP1389461A1 (en) * 2002-08-14 2004-02-18 Axxima Pharmaceuticals Aktiengesellschaft Pyrimidones with antiviral properties
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
US6737236B1 (en) 1997-01-08 2004-05-18 Proligo, Llc Bioconjugation of macromolecules
US7098326B2 (en) 2002-01-23 2006-08-29 Sigma-Aldrich Co. Methods for the integrated synthesis and purification of oligonucleotides
US7427678B2 (en) 1998-01-08 2008-09-23 Sigma-Aldrich Co. Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
US7615629B2 (en) 2002-12-31 2009-11-10 Sigma-Aldrich Co. Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8629263B2 (en) 2009-05-20 2014-01-14 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9284342B2 (en) 2009-05-20 2016-03-15 Gilead Pharmasset Llc Nucleoside phosphoramidates
US10287311B2 (en) 2003-05-30 2019-05-14 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US10577359B2 (en) 2004-09-14 2020-03-03 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3975374A (en) * 1970-12-21 1976-08-17 The Upjohn Company Process for preparing 2-thiouracil nucleosides
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3755295A (en) * 1969-10-24 1973-08-28 Syntex Corp 1-(2-amino-2-deoxy-{62 -d-ribofuranosyl) pyrimidines and derivatives thereof
US3975374A (en) * 1970-12-21 1976-08-17 The Upjohn Company Process for preparing 2-thiouracil nucleosides
US5212295A (en) * 1990-01-11 1993-05-18 Isis Pharmaceuticals Monomers for preparation of oligonucleotides having chiral phosphorus linkages

Cited By (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090932A (en) * 1994-06-22 2000-07-18 Proligo Llc Method of preparation of known and novel 2'-modified nucleosides by intramolecular nucleophilic displacement
US6737236B1 (en) 1997-01-08 2004-05-18 Proligo, Llc Bioconjugation of macromolecules
US7427678B2 (en) 1998-01-08 2008-09-23 Sigma-Aldrich Co. Method for immobilizing oligonucleotides employing the cycloaddition bioconjugation method
WO2000040590A3 (en) * 1999-01-05 2000-11-02 Bio Merieux Functionalised polynucleotide compound, optionally marked and method for detecting a target nucleic acid
US6875858B1 (en) 1999-01-05 2005-04-05 Bio Merieux Functionalized polynucleotide compound, optionally marked and method for detecting a target nucleic acid
WO2000040590A2 (en) * 1999-01-05 2000-07-13 Bio Merieux Functionalised polynucleotide compound, optionally marked and method for detecting a target nucleic acid
US7098326B2 (en) 2002-01-23 2006-08-29 Sigma-Aldrich Co. Methods for the integrated synthesis and purification of oligonucleotides
EP1389461A1 (en) * 2002-08-14 2004-02-18 Axxima Pharmaceuticals Aktiengesellschaft Pyrimidones with antiviral properties
WO2004016271A1 (en) * 2002-08-14 2004-02-26 Axxima Pharmaceuticals Ag Pyrimidones as antiviral agents
US7615629B2 (en) 2002-12-31 2009-11-10 Sigma-Aldrich Co. Methods and compositions for the tandem synthesis of two or more oligonucleotides on the same solid support
US10287311B2 (en) 2003-05-30 2019-05-14 Gilead Pharmasset Llc Modified fluorinated nucleoside analogues
US10577359B2 (en) 2004-09-14 2020-03-03 Gilead Pharmasset Llc Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives
US11642361B2 (en) 2007-03-30 2023-05-09 Gilead Sciences, Inc. Nucleoside phosphoramidate prodrugs
US9085573B2 (en) 2007-03-30 2015-07-21 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8580765B2 (en) 2007-03-30 2013-11-12 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8735372B2 (en) 2007-03-30 2014-05-27 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US10183037B2 (en) 2007-03-30 2019-01-22 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US9585906B2 (en) 2007-03-30 2017-03-07 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8906880B2 (en) 2007-03-30 2014-12-09 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8957046B2 (en) 2007-03-30 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidate prodrugs
US8716262B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8716263B2 (en) 2008-12-23 2014-05-06 Gilead Pharmasset Llc Synthesis of purine nucleosides
US8551973B2 (en) 2008-12-23 2013-10-08 Gilead Pharmasset Llc Nucleoside analogs
US8957045B2 (en) 2008-12-23 2015-02-17 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9045520B2 (en) 2008-12-23 2015-06-02 Gilead Pharmasset Llc Synthesis of purine nucleosides
US9284342B2 (en) 2009-05-20 2016-03-15 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9206217B2 (en) 2009-05-20 2015-12-08 Gilead Pharmasset Llc Nucleoside phosphoramidates
US9637512B2 (en) 2009-05-20 2017-05-02 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8642756B2 (en) 2009-05-20 2014-02-04 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8633309B2 (en) 2009-05-20 2014-01-21 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8629263B2 (en) 2009-05-20 2014-01-14 Gilead Pharmasset Llc Nucleoside phosphoramidates
US8859756B2 (en) 2010-03-31 2014-10-14 Gilead Pharmasset Llc Stereoselective synthesis of phosphorus containing actives
US9394331B2 (en) 2010-11-30 2016-07-19 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8841275B2 (en) 2010-11-30 2014-09-23 Gilead Pharmasset Llc 2′-spiro-nucleosides and derivatives thereof useful for treating hepatitis C virus and dengue virus infections
US8889159B2 (en) 2011-11-29 2014-11-18 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US9549941B2 (en) 2011-11-29 2017-01-24 Gilead Pharmasset Llc Compositions and methods for treating hepatitis C virus
US11116783B2 (en) 2013-08-27 2021-09-14 Gilead Pharmasset Llc Combination formulation of two antiviral compounds
US11707479B2 (en) 2013-08-27 2023-07-25 Gilead Sciences, Inc. Combination formulation of two antiviral compounds

Also Published As

Publication number Publication date
AU6550394A (en) 1995-09-25

Similar Documents

Publication Publication Date Title
US6369040B1 (en) Pyrimidine nucleosides
WO1995024185A1 (en) Novel pyrimidine nucleosides
JP3535519B2 (en) N-2-substituted purines
KR100274331B1 (en) Sugar modified nucleosides and their use for synthesis of oligonucleotides
EP0813539B1 (en) Improved process for the synthesis of 2&#39;-o-substituted pyrimidines and oligomeric compounds therefrom
KR0155574B1 (en) Back bone modified oligonucleotide analogs
US5658731A (en) 2&#39;-O-alkylnucleotides as well as polymers which contain such nucleotides
KR100399743B1 (en) Aminooxy-Modified Oligo nucleotides
US5561225A (en) Polynucleotide analogs containing sulfonate and sulfonamide internucleoside linkages
US6166197A (en) Oligomeric compounds having pyrimidine nucleotide (S) with 2&#39;and 5 substitutions
JP3050595B2 (en) Oligonucleotide analogues
EP1015469B2 (en) Bi- and tri-cyclic nucleoside, nucleotide and oligonucleoide analogues
US6914148B2 (en) Guanidinium functionalized intermediates
JPH05502031A (en) Compositions and methods for detecting and modulating RNA activity and gene expression
JPH06502758A (en) Sugar-modified oligonucleotides to detect and modulate gene expression
JP2002520420A (en) Oligonucleotides with site-specific chiral phosphorothioate internucleoside linkages
US20030096979A1 (en) Oligonucleotides having A-DNA form and B-DNA form conformational geometry
Wenzel et al. Self-Complementary Oligodeoxyribonucleotides Incorporating L-Related Isodeoxynucleosides: Synthesis, Physical Characterization, Enzymology, and CD Studies
EP0649429B1 (en) Heteroatomic oligonucleoside linkages
CN101410406B (en) 6-modified bicyclic nucleic acid analogs
AU2002325599B2 (en) Oligonucleotide analogues
CA2078256A1 (en) Synthesis of sulfide-linked di-or oligonucleotide analogs and incorporation into antisense dna or rna
WO1992021690A1 (en) Purine base modified 2&#39;-deoxyribonucleosides, use in triplex forming oligonucleotides and process for preparing the same
JPH06502655A (en) Oligo-2&#39;-deoxynucleotides and their use as pharmaceutical substances with antiviral activity

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB HU JP KP KR KZ LK LU LV MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TT UA UZ VN

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642